Article
Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma.
BMC health services research - 9 Apr 2022
Shen Chan, Holguin Rolfy A Perez, Schaefer Eric, Zhou Shouhao, Belani Chandra P, Ma Patrick C, Reed Michael F
Abstract excerpt
BACKGROUND: Guidelines in 2013 and 2014 recommended Epidermal Growth Factor Receptor (EGFR) testing for metastatic lung adenocarcinoma patients as the efficacy of targeted therapies depends on the mutations. However, adherence to these guidelines and the corresponding costs have not been well-studied. METHODS: We identified 2362 patients at least 65 years old newly diagnosed with metastatic lung adenocarcinoma...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.